Fuchs' Endothelial Dystrophy
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q4 2027.
- Q4 2027Descemet Endothelial Thickness Comparison Trials (DETECT I & II)
- Q4 2027Safety and Efficacy of Brief Intraoperative Corneal Endothelial Graft Incubation in Plasma Rich in Growth Factors (PRGF) for Reducing Postoperative Endothelial Cell Loss
- Q3 2028Optimized Immunosuppression for Corneal Transplantation: A Multi-center Randomized Controlled Clinical Trial
Clinical MilestonesViewHide
- 2026-05-08Descemet Endothelial Thickness Comparison Trials (DETECT I & II)Results expected Q4 2027
- 2026-04-09Safety and Efficacy of Brief Intraoperative Corneal Endothelial Graft Incubation in Plasma Rich in Growth Factors (PRGF) for Reducing Postoperative Endothelial Cell LossResults expected Q4 2027
- 2025-10-06Optimized Immunosuppression for Corneal Transplantation: A Multi-center Randomized Controlled Clinical TrialResults expected Q3 2028
- 2026-05-08ClinicalDescemet Endothelial Thickness Comparison Trials (DETECT I & II)Results expected Q4 2027
- 2026-04-09ClinicalSafety and Efficacy of Brief Intraoperative Corneal Endothelial Graft Incubation in Plasma Rich in Growth Factors (PRGF) for Reducing Postoperative Endothelial Cell LossResults expected Q4 2027
- 2025-12-09ClinicalPhase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal EdemaPrimary completion
- 2025-10-06ClinicalOptimized Immunosuppression for Corneal Transplantation: A Multi-center Randomized Controlled Clinical TrialResults expected Q3 2028
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes1
- Oxidative Stress1
Leading journals1
- Oxidative medicine and cellular longevity1
Leading researchers2
- Grzybowski A1
- Nita M1
Affiliations (unnormalised)2
- Domestic and Specialized Medicine Centre "Dilmed"1
- Poznan City Hospital1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Disorder caused by loss of endothelium of the central cornea. It is characterized by hyaline endothelial outgrowths on Descemet's membrane, epithelial blisters, reduced vision, and pain.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.